InvestorsHub Logo
Followers 75
Posts 5498
Boards Moderated 0
Alias Born 10/19/2006

Re: None

Wednesday, 11/07/2018 7:21:23 PM

Wednesday, November 07, 2018 7:21:23 PM

Post# of 1988
VKTX, of interest....Is the share offering / selling over?

Viking Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update

At September 30, 2018, Viking held cash, cash equivalents and short-term investments totaling $304.2 million. As of October 31, 2018, Viking had 71,459,857 shares of common stock outstanding.

Balance sheet strengthened through $176 million equity financing. In the third quarter of 2018, Viking raised approximately $176 million in gross proceeds through the issuance of common stock. These proceeds will be used to support the company's ongoing development programs, partnering efforts and other corporate activities.

During the third quarter, Viking received written correspondence from the FDA, in response to the company's Type C meeting questions related to potential registration endpoints that might be utilized to evaluate VK5211 in the hip fracture setting. The company is currently exploring partnering opportunities that will allow us to optimize the value of VK5211 and move the program forward in the most efficient manner possible.
https://finance.yahoo.com/news/viking-therapeutics-reports-third-quarter-210500048.html

Waiting for the 10q

GO VKTX

"PEACE"
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VKTX News